NASDAQ:ANIP ANI Pharmaceuticals - ANIP Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding ANI Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $44.67 -0.54 (-1.19%) (As of 02/3/2023 12:00 AM ET) Add Compare Share Share Today's Range$44.09▼$45.5050-Day Range$37.31▼$45.2152-Week Range$22.31▼$45.50Volume70,522 shsAverage Volume68,592 shsMarket Capitalization$780.38 millionP/E RatioN/ADividend YieldN/APrice Target$49.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability ANI Pharmaceuticals MarketRank™ ForecastAnalyst RatingModerate Buy2.67 Rating ScoreUpside/Downside9.7% Upside$49.00 Price TargetShort InterestHealthy1.86% of Shares Sold ShortDividend StrengthN/ASustainability-1.98Upright™ Environmental ScoreNews SentimentN/AInsider TradingN/AProj. Earnings Growth227.27%From $0.66 to $2.16 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.89 out of 5 starsMedical Sector678th out of 1,029 stocksPharmaceutical Preparations Industry341st out of 501 stocks 1.3 Analyst's Opinion Consensus RatingANI Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $49.00, ANI Pharmaceuticals has a forecasted upside of 9.7% from its current price of $44.67.Amount of Analyst CoverageANI Pharmaceuticals has received no research coverage in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted1.86% of the outstanding shares of ANI Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverANI Pharmaceuticals has a short interest ratio ("days to cover") of 4.6.Change versus previous monthShort interest in ANI Pharmaceuticals has recently decreased by 4.85%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldANI Pharmaceuticals does not currently pay a dividend.Dividend GrowthANI Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.2 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreANI Pharmaceuticals has received a 62.22% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Antihypertensives (C02)", "Beta blockers (C07)", "Macrolides", "Simvastatin", "Antifungal medication (D01) ", and "Memantine" products. See details.Environmental SustainabilityThe Environmental Impact score for ANI Pharmaceuticals is -1.98. Previous Next 0.6 News and Social Media Coverage Search Interest1 people have searched for ANIP on MarketBeat in the last 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, ANI Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders27.20% of the stock of ANI Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions67.89% of the stock of ANI Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for ANI Pharmaceuticals are expected to grow by 227.27% in the coming year, from $0.66 to $2.16 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ANI Pharmaceuticals is -9.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ANI Pharmaceuticals is -9.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioANI Pharmaceuticals has a P/B Ratio of 2.26. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About ANI Pharmaceuticals (NASDAQ:ANIP) StockANI Pharmaceuticals, Inc. is a bio-pharmaceutical company, which engages in developing, manufacturing, and marketing branded and generic prescription pharmaceuticals. Its areas of product development include narcotics, oncolytics, hormones and steroids, and complex formulations involving extended release and combination products. The company was founded on August 29, 1996 and is headquartered in Baudette, MN.Read More Receive ANIP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ANI Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address ANIP Stock News HeadlinesDecember 24, 2022 | thestreet.comANI Pharmaceuticals' Varied Offerings, Strategic Acquisitions Make It a Good Play for InvestorsDecember 22, 2022 | finance.yahoo.comThe past five years for ANI Pharmaceuticals (NASDAQ:ANIP) investors has not been profitableFebruary 4, 2023 | Investor Place Media (Ad)Cash Holders STILL Aren't Taking Steps to PrepareStocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.November 28, 2022 | markets.businessinsider.comANI Pharma: FDA Approves ANDA For Fluoxetine Oral SolutionNovember 28, 2022 | finance.yahoo.comANI Pharmaceuticals Announces the FDA Approval and Launch of Fluoxetine Oral Solution USPNovember 27, 2022 | finance.yahoo.comThis Biopharma 'Fits the Bill' as a Growth PlayNovember 16, 2022 | finance.yahoo.comANI Pharmaceuticals Announces the FDA Approval and Launch of Trimethoprim Tablets USPNovember 11, 2022 | finance.yahoo.comANI Pharmaceuticals Third Quarter 2022 Earnings: Revenues Beat Expectations, EPS LagsFebruary 4, 2023 | Wall Street Watch Dogs (Ad)“Future Fuel” will unleash $11 trillion wave of wealthThe next major energy revolution is unfolding right now. And it could hand early investors as much as 46,700% gains…November 9, 2022 | seekingalpha.comANI Pharmaceuticals, Inc. (ANIP) Q3 2022 Earnings Call TranscriptNovember 9, 2022 | finance.yahoo.comANI Pharmaceuticals (ANIP) Surpasses Q3 Earnings and Revenue EstimatesNovember 9, 2022 | markets.businessinsider.comANI Pharmaceuticals, Inc. Q3 Earnings SummaryNovember 9, 2022 | finance.yahoo.comANI Pharmaceuticals Reports Third Quarter 2022 Financial Results; Reports Record Net RevenuesOctober 24, 2022 | finance.yahoo.comANI Pharmaceuticals to Discuss Third Quarter 2022 Financial Results on November 9, 2022, at 8:00 a.m. ETSeptember 13, 2022 | benzinga.comANI Pharmaceuticals Appoints Krista Davis as...September 12, 2022 | finance.yahoo.comANI Pharmaceuticals Appoints Krista Davis as Chief Human Resources OfficerSeptember 7, 2022 | americanbankingnews.comANI Pharmaceuticals (NASDAQ:ANIP) Coverage Initiated by Analysts at HC WainwrightAugust 31, 2022 | finance.yahoo.comBullish ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) insiders filled their treasuries with US$1.0m worth of stock over last yearAugust 30, 2022 | finance.yahoo.comANI Pharmaceuticals to Present at the H.C. Wainwright 24th Annual Global Investment ConferenceAugust 29, 2022 | nasdaq.comANI Pharma To Launch Generic Version Of CompazineAugust 29, 2022 | finance.yahoo.comANI Pharmaceuticals Announces the Launch of Prochlorperazine Maleate Tablets USPAugust 20, 2022 | nasdaq.comDon't Ignore The Fact That This Insider Just Sold Some Shares In ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)August 16, 2022 | finance.yahoo.comANI Pharmaceuticals Announces FDA Approval and Imminent Launch of Dexamethasone Tablets USPAugust 16, 2022 | nasdaq.comShareholders in ANI Pharmaceuticals (NASDAQ:ANIP) are in the red if they invested three years agoAugust 8, 2022 | benzinga.comFull-Year 2022 Guidance:August 8, 2022 | seekingalpha.comANI Pharmaceuticals Q2 mixed earnings; raises FY 2022 revenue guidance for CortrophinAugust 8, 2022 | nasdaq.comANI Pharma Q2 Adj. Earnings Misses Estimates, Reiterates FY22 GuidanceSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive ANIP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ANI Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address ANIP Company Calendar Last Earnings11/09/2022Today2/03/2023Next Earnings (Estimated)3/21/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ANIP Previous SymbolNASDAQ:BPAX CUSIPN/A CIK1023024 Webwww.anipharmaceuticals.com Phone(218) 634-3500Fax218-634-3540Employees601Year FoundedN/APrice Target and Rating Average Stock Price Forecast$49.00 High Stock Price Forecast$50.00 Low Stock Price Forecast$48.00 Forecasted Upside/Downside+9.7%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($4.48) Trailing P/E RatioN/A Forward P/E Ratio67.68 P/E GrowthN/ANet Income$-42,600,000.00 Net Margins-23.95% Pretax Margin-31.01% Return on Equity2.65% Return on Assets1.13% Debt Debt-to-Equity Ratio0.92 Current Ratio3.79 Quick Ratio2.62 Sales & Book Value Annual Sales$216.14 million Price / Sales3.61 Cash Flow$4.75 per share Price / Cash Flow9.40 Book Value$19.73 per share Price / Book2.26Miscellaneous Outstanding Shares17,470,000Free Float12,715,000Market Cap$780.38 million OptionableOptionable Beta1.05 Key ExecutivesNikhil LalwaniPresident, Chief Executive Officer & DirectorJames G. MarkenSenior VP-Operations & Product DevelopmentStephen P. CareyChief Financial Officer & Senior VP-FinanceMuthusamy ShanmugamDirector & Head-Research & DevelopmentMary PaoChief Medical OfficerKey CompetitorsIntercept PharmaceuticalsNASDAQ:ICPTSummit TherapeuticsNASDAQ:SMMTDyne TherapeuticsNASDAQ:DYNAmarinNASDAQ:AMRNProvention BioNASDAQ:PRVBView All CompetitorsInsiders & InstitutionsSG Americas Securities LLCBought 4,005 shares on 2/2/2023Ownership: 0.023%Simplex Trading LLCBought 400 shares on 2/2/2023Ownership: 0.000%DekaBank Deutsche GirozentraleBought 10,000 shares on 2/1/2023Ownership: 0.057%DT Investment Partners LLCBought 1,280 shares on 1/31/2023Ownership: 0.007%BTC Capital Management Inc.Bought 8,217 shares on 1/27/2023Ownership: 0.047%View All Insider TransactionsView All Institutional Transactions ANIP Stock - Frequently Asked Questions Should I buy or sell ANI Pharmaceuticals stock right now? 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ANI Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ANIP shares. View ANIP analyst ratings or view top-rated stocks. What is ANI Pharmaceuticals' stock price forecast for 2023? 3 equities research analysts have issued 12 month target prices for ANI Pharmaceuticals' shares. Their ANIP share price forecasts range from $48.00 to $50.00. On average, they anticipate the company's stock price to reach $49.00 in the next twelve months. This suggests a possible upside of 9.8% from the stock's current price. View analysts price targets for ANIP or view top-rated stocks among Wall Street analysts. How have ANIP shares performed in 2023? ANI Pharmaceuticals' stock was trading at $40.23 at the beginning of 2023. Since then, ANIP shares have increased by 10.9% and is now trading at $44.63. View the best growth stocks for 2023 here. When is ANI Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 21st 2023. View our ANIP earnings forecast. How were ANI Pharmaceuticals' earnings last quarter? ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) issued its earnings results on Wednesday, November, 9th. The specialty pharmaceutical company reported $0.46 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.40 by $0.06. The specialty pharmaceutical company had revenue of $83.82 million for the quarter, compared to analysts' expectations of $78.71 million. ANI Pharmaceuticals had a positive trailing twelve-month return on equity of 2.65% and a negative net margin of 23.95%. What guidance has ANI Pharmaceuticals issued on next quarter's earnings? ANI Pharmaceuticals issued an update on its FY 2022 earnings guidance on Friday, December, 9th. The company provided EPS guidance of $1.34-$1.62 for the period, compared to the consensus EPS estimate of $1.37. The company issued revenue guidance of $295.00 million-$315.00 million, compared to the consensus revenue estimate of $302.88 million. What is Arthur Przbyl's approval rating as ANI Pharmaceuticals' CEO? 5 employees have rated ANI Pharmaceuticals Chief Executive Officer Arthur Przbyl on Glassdoor.com. Arthur Przbyl has an approval rating of 100% among the company's employees. This puts Arthur Przbyl in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 49.0% of employees surveyed would recommend working at ANI Pharmaceuticals to a friend. What other stocks do shareholders of ANI Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other ANI Pharmaceuticals investors own include Abraxas Petroleum (AXAS), Gilead Sciences (gild), Micron Technology (MU), AbbVie (ABBV), Teva Pharmaceutical Industries (TEVA), Alibaba Group (BABA), Broadcom (AVGO), Cisco Systems (CSCO), Exelixis (EXEL) and Intel (INTC). What is ANI Pharmaceuticals' stock symbol? ANI Pharmaceuticals trades on the NASDAQ under the ticker symbol "ANIP." Who are ANI Pharmaceuticals' major shareholders? ANI Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include Wedge Capital Management L L P NC (0.71%), Comerica Bank (0.27%), DekaBank Deutsche Girozentrale (0.06%), BTC Capital Management Inc. (0.05%), Yousif Capital Management LLC (0.04%) and Louisiana State Employees Retirement System (0.03%). Insiders that own company stock include James G Marken, Jeanne Thoma, Muthusamy Shanmugam, Nikhil Lalwani, Patrick D Walsh and Thomas Haughey. View institutional ownership trends. How do I buy shares of ANI Pharmaceuticals? Shares of ANIP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is ANI Pharmaceuticals' stock price today? One share of ANIP stock can currently be purchased for approximately $44.63. How much money does ANI Pharmaceuticals make? ANI Pharmaceuticals (NASDAQ:ANIP) has a market capitalization of $779.69 million and generates $216.14 million in revenue each year. The specialty pharmaceutical company earns $-42,600,000.00 in net income (profit) each year or ($4.48) on an earnings per share basis. How many employees does ANI Pharmaceuticals have? The company employs 601 workers across the globe. How can I contact ANI Pharmaceuticals? ANI Pharmaceuticals' mailing address is 210 Main Street West, Baudette MN, 56623. The official website for the company is www.anipharmaceuticals.com. The specialty pharmaceutical company can be reached via phone at (218) 634-3500, via email at ir@anipharmaceuticals.com, or via fax at 218-634-3540. This page (NASDAQ:ANIP) was last updated on 2/4/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.